Verastem Inc VSTM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors
-
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer
-
Verastem Doses First Patient in Pancreatic Cancer Trial
-
Verastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic Cancer
-
Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program
-
Verastem Oncology Gets FDA Fast Track Designation for Lung Cancer Drug
-
Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Trading Information
- Previous Close Price
- $5.53
- Day Range
- $5.24–5.47
- 52-Week Range
- $3.43–11.23
- Bid/Ask
- $5.31 / $5.33
- Shares Outstanding
- 87.87M
- Market Cap
- $466.61M
- Volume/Avg
- 532,908 / 3M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 8.25
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 102
- Website
- https://www.verastem.com
Valuation
|
Metric
|
VSTM
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 5.46 |
Price/Sales | 8.25 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
VSTM
|
|---|---|
Quick Ratio | 2.87 |
Current Ratio | 3.04 |
Interest Coverage | −148.37 |
Quick Ratio
VSTM
Profitability
|
Metric
|
VSTM
|
|---|---|
Return on Assets (Normalized) | −86.07% |
Return on Equity (Normalized) | −663.19% |
Return on Invested Capital (Normalized) | −155.82% |
Return on Assets
VSTM
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|yG!J?By | LOCK|>#n@^ | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|wRBS%?v | LOCK|vjBH | $70B | |||
| argenx SE ADR
ARGX
| LOCK|<F@g&? | LOCK|S< | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|tt<hwJZ | LOCK|Q$?g | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|YDQ?h& | LOCK|!? | $36B | |||
| Moderna Inc
MRNA
| LOCK|vjH>rvT | LOCK|$? | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|xRz%Y<k | LOCK|Lrl^J | $25B | |||
| Incyte Corp
INCY
| LOCK|&XD!W@ | LOCK|W@f | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|m@q%rJ! | LOCK|^^y | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|Rh%#sz | LOCK|Htb | $17B |
United States